Brendan Ogrady

Mr. Brendan O’Grady is Chief Executive Officer – Global Formulations Business and leads the Commercial Business Units for Glenmark Pharmaceuticals Ltd. He provides strategic leadership for bringing greater focus and alignment across all regions and therapeutic areas, to better serve the needs of patients globally.

Mr. O’Grady has over three decades of rich experience in generics, specialty, biologic, and biosimilar products where he has successfully led and transformed businesses for growth across multiple geographies. Prior to joining Glenmark, he was Chief Growth & Commercial Officer for Amwell, Inc. providing strategic leadership to Amwell’s global business operations. Mr. O’Grady has previously been associated with Teva Pharmaceuticals, Inc, as the President & CEO, Teva USA and EVP, North America Commercial. He was instrumental in stabilizing and growing the North American business, revitalizing the Global Specialty strategy, and making significant contributions to market access strategies, brand acquisitions, and integrations during his over two decade association with the organization. He has also had significant and successful stints with Sanofi Pharmaceuticals and SC Johnson (Wax) & Son at the beginning of his career.

Mr. O’Grady has a Master’s degree in Business Administration from Baker University, Kansas. He also holds a Bachelor of Science degree in Management Science & Marketing from State University of New York.